Pharmaceutical Fronts : Impact Factor & More
eISSN: 2628-5096pISSN: 2628-5088
Open AccessShare this on:
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Pharmaceutical Fronts Journal Specifications
Indexed in the following public directories
DOAJ
| Overview | |
| Publisher | Georg Thieme Verlag KG |
| Language | English |
| Publication Time | 15 |
| Editorial Review Process | Double anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Shanghai Institute of Pharmaceutical Industry |
| Website URL | Visit website |
| Publication Details | |
| Publication Time | 15 |
| Waiver Policy | Visit website |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC-ND |
| OA statement | Visit website |
View less
Planning to publish in Pharmaceutical Fronts ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Pharmaceutical Fronts
Chemistry-Driven Integrated Innovation: Unleashing the Potential of PROTAC Technology
- 15 Dec 2025
- Pharmaceutical Fronts
An Improved Synthesis Route of Molnupiravir and its Key Impurities
- 11 Dec 2025
- Pharmaceutical Fronts
Degradation of Cyclin-Dependent Kinase: A New Weapon for Cancer Therapy
- 11 Dec 2025
- Pharmaceutical Fronts
Virtual Screening of Anti-HIV Leads from Mayana (Coleus scutellarioides Benth.) Phytoconstituents
- 25 Nov 2025
- Pharmaceutical Fronts
Development of Novel Tavapadon Analogs as Dual-targeted Partial Agonists Based on the Dopamine D1/D5 Receptors
- 28 Jul 2025
- Pharmaceutical Fronts
High-Yield Biosynthesis Process and Characterization of Brolucizumab
- 18 Jul 2025
- Pharmaceutical Fronts
Chemistry-Driven Integrated Innovation: Unleashing the Potential of PROTAC Technology
- 15 Dec 2025
- Pharmaceutical Fronts
An Improved Synthesis Route of Molnupiravir and its Key Impurities
- 11 Dec 2025
- Pharmaceutical Fronts
Degradation of Cyclin-Dependent Kinase: A New Weapon for Cancer Therapy
- 11 Dec 2025
- Pharmaceutical Fronts
Virtual Screening of Anti-HIV Leads from Mayana (Coleus scutellarioides Benth.) Phytoconstituents
- 25 Nov 2025
- Pharmaceutical Fronts
Development of Novel Tavapadon Analogs as Dual-targeted Partial Agonists Based on the Dopamine D1/D5 Receptors
- 28 Jul 2025
- Pharmaceutical Fronts
High-Yield Biosynthesis Process and Characterization of Brolucizumab
- 18 Jul 2025
- Pharmaceutical Fronts
FAQs on Pharmaceutical Fronts
How many articles did Pharmaceutical Fronts publish last year? 
What is the eISSN & pISSN for Pharmaceutical Fronts?
Who is the publisher of Pharmaceutical Fronts?
